** Casi Pharmaceuticals' shares fall 14.89% to $2.40 premarket
** Co says its application to start trials for its experimental antibody in patients with a type of complication related to kidney transplants was placed on clinical hold
** The complication, known as Antibody Mediated Rejection, occurs after a transplant when the recipient's immune system produces antibodies that attack the transplanted organ
** Co's application supporting early-to-mid stage trial of the antibody in adults with chronic immune thrombocytopenia, a rare autoimmune blood disorder, remains open
** Up to last close, stock down ~60% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。